These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9333933

  • 1. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
    Szucs TD, Goedde M, Berger K, Kiowski W.
    Schweiz Med Wochenschr; 1997 Jul 22; 127(29-30):1234-41. PubMed ID: 9333933
    [Abstract] [Full Text] [Related]

  • 2. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T, Berger K, Schulte-Hillen J, Kleber FX.
    Med Klin (Munich); 1996 Feb 15; 91(2):112-8. PubMed ID: 8850108
    [Abstract] [Full Text] [Related]

  • 3. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 15; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 4. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure.
    Paul SD, Kuntz KM, Eagle KA, Weinstein MC.
    Arch Intern Med; 1994 May 23; 154(10):1143-9. PubMed ID: 8185426
    [Abstract] [Full Text] [Related]

  • 5. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun 23; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 6. [A Czech and Slovak interventional study of spirapril (the CASSIS study). A randomized, double-blind, multicenter, placebo-controlled study in chronic heart failure].
    Jerie P, Kremer HJ, Uhlír O, Widimský J.
    Vnitr Lek; 1997 Jun 23; 43(6):351-8. PubMed ID: 9601863
    [Abstract] [Full Text] [Related]

  • 7. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ, CARMEN investigators and co-ordinators.
    Eur J Heart Fail; 2004 Jun 23; 6(4):467-75. PubMed ID: 15182773
    [Abstract] [Full Text] [Related]

  • 8. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
    Parker AB, Yusuf S, Naylor CD.
    Am Heart J; 2002 Dec 23; 144(6):941-7. PubMed ID: 12486418
    [Abstract] [Full Text] [Related]

  • 9. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC, Nilsson C, Hervas-Malo M, Jacobs P, Tsuyuki RT.
    Can J Cardiol; 2005 Dec 23; 21(14):1301-6. PubMed ID: 16341301
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 23; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 11. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
    Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A.
    Circulation; 2003 Jun 17; 107(23):2926-31. PubMed ID: 12771010
    [Abstract] [Full Text] [Related]

  • 12. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    Yusuf S.
    Herz; 1993 Dec 17; 18 Suppl 1():444-8. PubMed ID: 8125425
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
    Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA.
    J Am Coll Cardiol; 2005 Feb 01; 45(3):391-9. PubMed ID: 15680718
    [Abstract] [Full Text] [Related]

  • 14. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM.
    Circulation; 2004 Aug 10; 110(6):724-31. PubMed ID: 15289383
    [Abstract] [Full Text] [Related]

  • 15. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
    Alsheikh-Ali AA, Wang PJ, Rand W, Konstam MA, Homoud MK, Link MS, Estes NA, Salem DN, Al-Ahmad AM.
    Am Heart J; 2004 Jun 10; 147(6):1061-5. PubMed ID: 15199356
    [Abstract] [Full Text] [Related]

  • 16. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
    Glick H, Cook J, Kinosian B, Pitt B, Bourassa MG, Pouleur H, Gerth W.
    J Card Fail; 1995 Dec 10; 1(5):371-80. PubMed ID: 12836712
    [Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia.
    Butler JR, Fletcher PJ.
    Aust N Z J Med; 1996 Feb 10; 26(1):89-95. PubMed ID: 8775534
    [Abstract] [Full Text] [Related]

  • 18. [The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII].
    Dessì-Fulgheri P, Paci MV, Rappelli A.
    Ann Ital Med Int; 1994 Oct 10; 9 Suppl():16S-18S. PubMed ID: 7857751
    [Abstract] [Full Text] [Related]

  • 19. Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction.
    Scott WG, Scott HM.
    Pharmacoeconomics; 1996 Feb 10; 9(2):156-67. PubMed ID: 10160094
    [Abstract] [Full Text] [Related]

  • 20. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M, Pogue J, Kindermann I, Pöss J, Koon T, Yusuf S.
    Eur J Heart Fail; 2014 Mar 10; 16(3):325-33. PubMed ID: 24464788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.